X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TORRENT PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TORRENT PHARMA GLENMARK PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 14.2 27.5 51.6% View Chart
P/BV x 4.0 6.7 59.1% View Chart
Dividend Yield % 0.3 3.0 10.8%  

Financials

 GLENMARK PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
TORRENT PHARMA
Mar-16
GLENMARK PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2621,720 73.4%   
Low Rs6721,134 59.2%   
Sales per share (Unadj.) Rs270.6394.5 68.6%  
Earnings per share (Unadj.) Rs24.9101.8 24.4%  
Cash flow per share (Unadj.) Rs34.4116.3 29.6%  
Dividends per share (Unadj.) Rs2.0040.00 5.0%  
Dividend yield (eoy) %0.22.8 7.4%  
Book value per share (Unadj.) Rs151.3200.3 75.6%  
Shares outstanding (eoy) m282.16169.22 166.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.63.6 98.8%   
Avg P/E ratio x38.914.0 277.2%  
P/CF ratio (eoy) x28.112.3 229.0%  
Price / Book Value ratio x6.47.1 89.7%  
Dividend payout %8.039.3 20.5%   
Avg Mkt Cap Rs m272,778241,435 113.0%   
No. of employees `00010.010.9 92.0%   
Total wages/salary Rs m13,7828,559 161.0%   
Avg. sales/employee Rs Th7,614.96,129.6 124.2%   
Avg. wages/employee Rs Th1,374.8785.8 175.0%   
Avg. net profit/employee Rs Th700.21,581.3 44.3%   
INCOME DATA
Net Sales Rs m76,34066,764 114.3%  
Other income Rs m3562,156 16.5%   
Total revenues Rs m76,69668,920 111.3%   
Gross profit Rs m14,17227,204 52.1%  
Depreciation Rs m2,6912,461 109.4%   
Interest Rs m1,7891,859 96.2%   
Profit before tax Rs m10,04825,041 40.1%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-1,403 0.0%   
Tax Rs m3,0286,414 47.2%   
Profit after tax Rs m7,01917,224 40.8%  
Gross profit margin %18.640.7 45.6%  
Effective tax rate %30.125.6 117.7%   
Net profit margin %9.225.8 35.6%  
BALANCE SHEET DATA
Current assets Rs m59,09646,622 126.8%   
Current liabilities Rs m40,01832,843 121.8%   
Net working cap to sales %25.020.6 121.1%  
Current ratio x1.51.4 104.0%  
Inventory Days Days7574 101.0%  
Debtors Days Days11979 150.9%  
Net fixed assets Rs m39,07539,029 100.1%   
Share capital Rs m282846 33.3%   
"Free" reserves Rs m30,28131,400 96.4%   
Net worth Rs m42,70333,890 126.0%   
Long term debt Rs m24,87318,637 133.5%   
Total assets Rs m111,02690,136 123.2%  
Interest coverage x6.614.5 45.7%   
Debt to equity ratio x0.60.5 105.9%  
Sales to assets ratio x0.70.7 92.8%   
Return on assets %7.921.2 37.5%  
Return on equity %16.450.8 32.3%  
Return on capital %17.548.5 36.1%  
Exports to sales %43.343.3 99.9%   
Imports to sales %7.46.9 108.2%   
Exports (fob) Rs m33,04428,934 114.2%   
Imports (cif) Rs m5,6724,584 123.7%   
Fx inflow Rs m36,94529,185 126.6%   
Fx outflow Rs m61,0666,021 1,014.3%   
Net fx Rs m-24,12223,165 -104.1%   
CASH FLOW
From Operations Rs m3,44927,132 12.7%  
From Investments Rs m-8,802-7,014 125.5%  
From Financial Activity Rs m6,986-14,352 -48.7%  
Net Cashflow Rs m9345,767 16.2%  

Share Holding

Indian Promoters % 48.3 71.5 67.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.0 98.3%  
FIIs % 34.4 12.6 273.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   56,727 26,511 214.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Novartis India Rallies 7%(Closing)

Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement this week.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

The Recipe to Over 60% Returns in Less Than a Year(The 5 Minute Wrapup)

Sep 9, 2017

Short term crisis in some companies could unveil some great investing opportunities.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 21, 2017 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS